Drug Profile
VK 0612
Alternative Names: MB 07803; VK-0612Latest Information Update: 24 Mar 2023
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Developer Viking Therapeutics
- Class Amino acids; Antihyperglycaemics; Oxazoles; Thiazoles
- Mechanism of Action Fructose bisphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 24 Mar 2023 Viking Therapeutics completes a phase IIa trial in Type 2 diabetes in USA (Viking Therapeutics pipeline, March 2023)
- 31 Dec 2022 Viking Therapeutics has patents pending for VK 0612 in India
- 21 Mar 2017 Viking Therapeutics has patent protection and a pending patent application for VK 0612 in USA, China, Hong Kong, Israel, Korea, Mexico, India, Indonesia and New Zealand